


# Evaluation de la réponse thérapeutique

**Tumeurs  
hématologiques**



**Tumeurs solides**

## Measurement of Clinical and Subclinical Tumour Response Using [ $^{18}\text{F}$ ]-fluorodeoxyglucose and Positron Emission Tomography: Review and 1999 EORTC Recommendations

H. Young,<sup>1</sup> R. Baum,<sup>2</sup> U. Cremerius,<sup>3</sup> K. Herholz,<sup>4</sup> O. Hoekstra,<sup>5</sup> A.A. Lammertsma,<sup>5</sup> J. Pruim<sup>6</sup> and P. Price<sup>1</sup> on behalf of the European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

*Eur J Cancer*, Vol. 35, No. 12, pp. 1772-1782, 1999

## Consensus Recommendations for the Use of $^{18}\text{F}$ -FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials

Lalitha K. Shankar<sup>1</sup>, John M. Hoffman<sup>2</sup>, Steve Bacharach<sup>3</sup>, Michael M. Graham<sup>4</sup>, Joel Karp<sup>5</sup>, Adriaan A. Lammertsma<sup>6</sup>, Steven Larson<sup>7</sup>, David A. Mankoff<sup>8</sup>, Barry A. Siegel<sup>9</sup>, Annick Van den Abbeele<sup>10</sup>, Jeffrey Yap<sup>10</sup>, and Daniel Sullivan<sup>1</sup>

THE JOURNAL OF NUCLEAR MEDICINE • Vol. 47 • No. 6 • June 2006

Dr Julien  
Dubreuil

## From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

Richard L. Wahl<sup>1,2</sup>, Heather Jacene<sup>1</sup>, Yvette Kasamon<sup>2</sup>, and Martin A. Lodge<sup>1</sup>

<sup>1</sup>Division of Nuclear Medicine, Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and  
<sup>2</sup>Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland

# Pour Qui ?

Use of [ $^{18}\text{F}$ ]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [ $^{18}\text{F}$ ]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

Bruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, Kaldoun Kerrou, Jean-Marc Ferrero, Thierry Petit, Pierre Kerbrat, Pierre-François Dupré, Thomas Bachelot, Philippe Gabelle, Sylvia Giard, David Coeffic, Philippe Bougnoux, Jean-Briac Prevost, Gilles Paintaud, Gilles Thibault, Juana Hernandez, Mathieu Coudert, Laurent Arnould, Alina Berriolo-Riedinger

## Modèle néoadjuvant



The  
**Oncologist**<sup>®</sup>

Breast Cancer

### Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer


OLIVIER HUMBERT,<sup>a,c,d</sup> ALEXANDRE COCHET,<sup>a,d</sup> BRUNO COUDERT,<sup>b</sup> ALINA BERRIOLO-RIEDINGER,<sup>a</sup> SALIM KANOUN,<sup>a</sup> FRANÇOIS BRUNOTTE,<sup>a,c</sup> PIERRE FUMOLEAU<sup>b</sup>

Departments of <sup>a</sup>Nuclear Medicine and <sup>b</sup>Medical Oncology, Centre G.F. Leclerc, Dijon, France; <sup>c</sup>Imaging Department, Centre Hospitalo-Universitaire Le Bocage, Dijon, France; <sup>d</sup>Université de Bourgogne, UMR CNRS 6306, Dijon, France

*Disclosures of potential conflicts of interest may be found at the end of this article.*

Key Words. Breast • Cancer • Positron emission tomography •  $^{18}\text{F}$ -Fluorodeoxyglucose • Response • Monitoring

Dr Olivier Humbert  
Dr MA Mouret Reygner



Immunothérapie?

**Predictive value of early  $^{18}\text{F}$ -FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study**

Christos Sachpekidis • Lionel Larribere • Leyun Pan •  
Uwe Haberkorn • Antonia Dimitrakopoulou-Strauss •  
Jessica C. Hassel

Received: 11 August 2014 / Accepted: 15 October 2014

Pr Frédéric Courbon